We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.

About ID-ODS Adult

ID – ODS Adult, your next step closer to personalized medicine (tm)

Individually Designed Optimum Dosing Strategies, or ID – ODS, is a simulation resource tool with extensive model library built from population pharmacokinetic models published in high quality, peer reviewed literature. The application is designed to aid health care professionals in the optimal dosing and continuous therapeutic monitoring of medications at the bedside. Enter all clinically relevant information through a user friendly interface to generate priori dosing regimens or to supply concentration data for posteriori dose adjustments in the adult patient population via Monte Carlo simulation and individual pharmacokinetic parameter optimization via Bayesian feedback.

What's New in the Latest Version 2.7.0

Last updated on Apr 23, 2019

2.7: New settings
2.6: PK target, user-defined dosing regiments
2.5 Amoxicillin, Flucloxacillin
2.4: patients tab
2.3: Vanco AUC calc
2.2: conventional & SI units
2.0: new UI
0.1.18: Telavancin, Tigecycline
0.1.17: Ceftriaxone, Levofloxacin, Polymyxin
0.1.16: Doripenem
0.1.14: Daptomycin
0.1.10: Ciprofloxacin
0.1.9: Meropenem
0.1.8: Pip. and Tazo.
0.1.7: Ceftazidime
0.1.6: MyDose
0.1.3: Vancomycin
0.1.2: Aminoglycoside
0.1.0: Three commonly used antibiotics

Translation Loading...

Additional APP Information

Latest Version

Request ID-ODS Adult Update 2.7.0

Uploaded by

سهيل رجباني

Requires Android

Android 4.1+

Show More

ID-ODS Adult Screenshots

Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.